ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0242490 | A disorder occurring at the site of insertion of TENDONS or LIGAMENTS into bones or JOINT CAPSULES. | Enthesopathy of unspecified site, NOS|unspecified enthesopathy|Enthesopathy of unspecified site|Enthesopathy|Enthesopathy of specified site|Enthesopathies|enthesopathy|Unspecified enthesopathy|Enthesopathy (disorder)|enthesopathies | Enthesopathy |
C0010073 | Spasm of the large- or medium-sized coronary arteries. | Coronary spasm|spasm coronary artery|Coronary artery spasm (disorder)|coronaries spasm|Coronary Artery Vasospasm|artery coronary spasms|CORONARY ARTERY SPASM|Coronary vasospasm|coronary artery spasm|CORONARY SPASM|Vasospasm, Coronary|vasospasm coronary|Coronary Artery Vasospasms|Artery Vasospasms, Coronary|Artery Vasospasm, Coronary|Coronary artery vasospasm|Vasospasms, Coronary Artery|coronary spasm|Vasospasm, Coronary Artery|Coronary Vasospasm|coronary spasms|Coronary Vasospasms|Vasospasms, Coronary|coronary vasospasms|arteriospasm coronary|coronary artery vasospasm|Coronary artery spasm|artery coronary spasm|coronary vasospasm|ARTERIOSPASM CORONARY|SPASM CORONARY ARTERY | Coronary Artery Vasospasm |
C0015895 | The capacity to conceive or to induce conception. It may refer to either the male or female. | Fertility, NOS|fertile|Ability to conceive|Fecundability|fecundability|fertility|fecundity|Fertile|Ability to conceive (observable entity)|Fertility, function (observable entity)|fertilities|Fertility|Fecundity|Fertility, function | Fertility |
C0458452 | The 8 inch long tube carrying urine from the bladder to the outside of the body exiting at the end of the penis. | Male urethral structure (body structure)|Urethra masculina|Male urethra|urethra male|male urethra|Male Urethra|Male urethral structure | Male urethral structure |
C0410000 | An autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. These typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren syndrome; in pediatrics the respective pediatric entities are encountered. | overlapping syndrome|overlaps syndrome|overlap syndromes|Overlap syndrome|Overlap Syndrome|Overlap syndrome (disorder)|overlap syndrome | Overlap syndrome |
C0155502 | Idiopathic recurrent VERTIGO associated with POSITIONAL NYSTAGMUS. It is associated with a vestibular loss without other neurological or auditory signs. Unlike in LABYRINTHITIS and VESTIBULAR NEURONITIS, inflammation in the ear is not observed. | BPPV|Vertigo, Benign Recurrent|Benign Paroxysmal Positional Vertigo|Vestibulopathy, Familial|Recurrent Vertigos, Benign|positional benign vertigo|BENIGN POSITIONAL VERTIGO|Benign paroxysmal positional vertigo (disorder)|positional vertigo benign|NYSTAGMUS, PAROXYSMAL POSITIONAL, BENIGN|Vestibulopathies, Familial|BPPV - Benign paroxysmal positional vertigo|VERTIGO, BENIGN PAROXYSMAL POSITIONAL|Familial Vestibulopathy|Familial Benign Recurrent Vertigo|BRV|Benign recurrent vertigo (disorder)|NYSTAGMUS, POSITIONAL, LABYRINTHINE|Benign paroxysmal positional nystagmus|Benign Recurrent Vertigo|Recurrent Vertigo, Benign|Benign recurrent vertigo|VERTIGO, BENIGN RECURRENT|Benign paroxysmal positional vertigo|Vertigo, Benign Paroxysmal Positional|VERTIGO, PAROXYSMAL POSITIONAL, BENIGN|VESTIBULOPATHY, FAMILIAL|Familial Vestibulopathies|vertigo benign positional|Benign Recurrent Vertigos|benign positional vertigo | Benign Paroxysmal Positional Vertigo |
C0271386 | Vertical nystagmus may present with either up-beating or down-beating eye movements or both. When present in the straight-ahead position of gaze it is referred to as upbeat nystagmus or downbeat nystagmus. [HPO:probinson] | Nystagmus, Vertical|Vertical nystagmus|Nystagmus, vertical|Vertical nystagmus (disorder) | Vertical Nystagmus |
C1517034 | A tube extending from the middle ear to the outer ear. | Horizontal Canal | External Canal |
C0006287 | A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS. | Ventilator lung in newborn|bronchopulmonary dysplasia (BPD)|Bronchopulmonary Dysplasia|BRONCHOPULMONARY DYSPLASIA|bronchopulmonary dysplasia|Bronchopulmonary dysplasia|BPD|Dysplasia, Bronchopulmonary|Bronchopulmonary dysplasia of newborn (disorder)|BPD - Bronchopulmonary dysplasia|Perinatal bronchopulmonary dysplasia|chronic lung disease of babies|Bronchopulmonary dysplasia of newborn|Chronic lung disease of prematurity | Bronchopulmonary Dysplasia |
C0011321 | The measurement of the density of a material by measuring the amount of light or radiation passing through (or absorbed by) the material. | densitometric scan|densitometry|densitometric scanning|Densitometry|Densitometries | Densitometry |
C0807955 | The property possessed by a line or surface that departs from the horizontal; the tangent of the angle it forms with the positive X axis. | sloped|slope|slopes|sloping | Slope |
C0521990 | null | Associated sign (finding)|Associated sign | Associated sign |
C0022548 | A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues. | keloid|Keloid scar|Keloid|keloids scars|Keloids|scar keloid|Cheloid of skin|keloid scar|cheloids|Keloid (morphologic abnormality)|cheloid|Keloid of skin|keloid skin disorder|Keloid scar of skin|KELOID|keloids|Keloid scar (disorder)|keloid skin|keloids skin|keloid scarring|keloid scars|Cheloid|Keloid cicatrix | Keloid |
C0017526 | Multinucleated masses produced by the fusion of many cells; often associated with viral infections. In AIDS, they are induced when the envelope glycoprotein of the HIV virus binds to the CD4 antigen of uninfected neighboring T4 cells. The resulting syncytium leads to cell death and thus may account for the cytopathic effect of the virus. | Polykaryocyte (cell)|MULTINUCLEATED GIANT CELL|Syncytium|syncytia|multinucleated giant cell|giant cells|Cells, Multinucleated Giant|Giant cell|Multinucleate giant cell (cell)|multinucleated giant cells|Abnormal numbers of nuclei|syncytium|Giant Cells, Multinucleated|Giant Cells|Multinucleated giant cell|Multinucleate giant cell|Polykaryocyte|Multinucleated cell|Cell, Multinucleated Giant|Polykaryocytes|Giant Cell|Multinucleated cell mass from fused cells (cell)|Multinucleated Giant Cells|giant cell|Multinucleate cell, NOS|Multinucleated Giant Cell|Cells, Giant|Multinucleate cell|Cell, Giant|Giant Cell, Multinucleated|Syncytia|Multinucleate giant cell, NOS|Multinucleated cell mass from fused cells|Giant cell, NOS | Giant Cells |
C0815275 | null | subcortical | subcortical |
C0011269 | An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44) | Vascular dementia (disorder)|Vascular Dementia|VAD - Vascular dementia|vascular dementia|Dementias, Vascular|Vascular dementia|Vascular dementia, NOS|dementia vascular|Vascular Dementias | Dementia, Vascular |
C0225990 | null | Large vessels|Large blood vessel structure (body structure)|Large vessels, NOS|Large vessel | Large blood vessel structure |
C0020846 | An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). | Immunoglobulins, E|Immunoglobulin IgE, NOS|immunoglobulin E|Immunoglobulin E (substance)|Immunoglobulin E|immunoglobulins e|IgE|Immunoglobulin IgE|immunoglobulin E (IgE)|IgE - Immunoglobulin E|immunoglobulin e | Immunoglobulin E |
C0004827 | Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes. | basophilic leukocyte|Basophilic Leukocyte|Basophil|Basophils|basophilic granulocyte|basophils|Basophil leukocyte|Basophil granulocyte|Marrow basophil|basophil|Blood basophil|Basophilic Granulocyte | Basophils |
C0001551 | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. | Immunostimulants|Immunological adjuvants|Immune enhancement agent (product)|immunomodulator|Immunoactivators|immunostimulant|Immune enhancement agent (substance)|Immunostimulant|Adjuvant, Immunological|immunologic adjuvant|Immune enhancement agent|immunostimulants|immunopotentiator|Immunoadjuvants|Immunological Adjuvants|Adjuvant, NOS|Immune enhancement agent, NOS|immunomodulators|immunological adjuvant|IMMUNOSTIMULANTS|Immunological Adjuvant|Adjuvant, Immunologic|Immunologic Adjuvants|IMMUNE ENHANCEMENT AGENTS|Adjuvant|immune adjuvant|Immunologic adjuvant|Adjuvants, Immunological|Immunoadjuvant|immunoadjuvant|Immunologic adjuvant (substance)|Immunologic Adjuvant|Adjuvants, Immunologic|Immunopotentiators | Immunologic Adjuvants |
C0226029 | null | Entire LCA - Left coronary artery|Entire LMS - Left main stem|Entire left coronary artery|Entire left main stem|Entire left coronary artery (body structure) | Entire left coronary artery |
C0342649 | Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS. | Vascular Calcinoses|Vascular calcifications|Vascular calcification|Vascular Calcifications|Calcifications, Vascular|Vascular calcification (disorder)|vascular calcification|calcifications vascular|Calcification, Vascular|Calcinosis, Vascular|Calcinoses, Vascular|Vascular Calcification|Vascular Calcinosis | Vascular calcification |
C0264683 | null | ATHEROMA CORONARY ARTERY|coronary artery atheroma|CORONARY ATHEROMA|Coronary artery atheroma|coronary atheroma|Coronary artery atheroma (disorder)|Coronary atheroma | Coronary artery atheroma |
C0161816 | Any heart or vascular disorder occurring as a consequence of injury to the cardiovascular system. | Cardiac complication, NOS|complications heart|complications cardiac|cardiac complications|Cardiovascular Complication|Cardiac complications of care|cardiac complication|complication heart|cardiovascular complications|Cardiac complications|Cardiac complication (disorder) | Cardiac complication |
C0085681 | A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum. | hyperphosphatemia|HYPERPHOSPHATEMIA|Hyperphosphataemia|hyperphosphataemia|HYPERPHOSPHATAEMIA|Hyperphosphatemia|Hyperphosphatemias|Hyperphosphatemia (disorder) | Hyperphosphatemia (disorder) |
C0585943 | null | Lipid-lowering therapy (procedure) | Lipid-lowering therapy |
C0239981 | A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA). | Serum albumin low|Low blood albumin|HYPOALBUMINEMIA|hypoalbuminaemia|hypoalbuminemia|Hypoalbuminaemia|Hypoalbuminemia (disorder)|Hypoalbuminemia | Hypoalbuminemia |
C0010340 | A disease or state in which death is possible or imminent. | Illnesses, Critical|Illness, Critical|critical illness|Critical Illnesses|Critically ill|Critically Ill|critically ill | Critical Illness |
C0053336 | null | BERAPROST|1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt|4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate|Beraprost|2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic Acid|1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-|beraprost | beraprost |
C0252643 | A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan decreases both pulmonary and systemic vascular resistance and is particularly used in the treatment of pulmonary arterial hypertension. | Product containing bosentan (medicinal product)|bosentanum|p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide|Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-|Bosentan (substance)|4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide|4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide|Bosentan-containing product|bosentán|Bosentan|bosentan|4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide|BOSENTAN | bosentan |
C0033567 | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). | prostacyclin|Prostaglandin PGI>2<|Prostaglandin PGI<sub>2</sub>|Prostaglandin X|pgx|pgi2|Prostaglandin I2|prostacyclin pgi2|PGI2|Epoprostenol-containing product|(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid|Prostacyclin|PGX|Epoprostenol|Epoprostenol (substance)|Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-|Epoprostanol|prostaglandin X|EPOPROSTENOL|epoprostenol|Prostaglandin I(2)|Prostaglandin PGI2|Product containing epoprostenol (medicinal product)|prostaglandin I2|(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate | epoprostenol |
C0079281 | A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63) | endothelin-1|Endothelin-1|Endothelin 1|1 endothelin|Endothelin Type 1|endothelin 1 | Endothelin-1 |
C0456261 | The resistance to blood flow offered by the pulmonary vasculature, which is normally one sixth of SVR. The major determinant of PVR is pulmonary vessel constriction, most often caused by hypoxia and/or hypercardia. Prolonged elevated PVR can cause right heart failure. | PVR - Pulmonary vascular resistance|Pulmonary vascular resistance (observable entity)|pulmonary vascular resistance|Resistance, Pulmonary Vascular|Vascular Resistance, Pulmonary|Pulmonary vascular resistance|PVR|Pulmonary Vascular Resistance | Pulmonary Vascular Resistance |
C0020542 | Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. | PHT - Pulmonary hypertension|HYPERTENSION PULMONARY|pulmonary hypertension|pulmonary hypertension disorder|Pulmonary hypertension (disorder)|PULMONARY HYPERTENSION|Pulmonary hypertension|Pulmonary hypertension, NOS|Pulmonary hypertension NOS|Hypertensive pulmonary vascular disease|hypertension caused by lung disease|Pulmonary Hypertension|Hypertension, pulmonary|Hypertension, Pulmonary | Pulmonary Hypertension |
C0014257 | A layer of epithelium that lines the heart, blood vessels (ENDOTHELIUM, VASCULAR), lymph vessels (ENDOTHELIUM, LYMPHATIC), and the serous cavities of the body. | Endothelium, NOS|Endotheliums|Endothelial tissue, NOS|Endothelium|Structure of endothelium tissue (body structure)|Endothelial tissue|endothelium|Endothelial|Structure of endothelium tissue|endothelial tissue | Endothelium |
C0003009 | An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. | Angiotensin-(1-8) Octapeptide|angiotensin ii|ANG-(1-8)Octapeptide|Angiotensin 2|2 angiotensin|angiotensin 2|angiotensin II|isoleucine5-angiotensin II|Angiotonin|ANGIOTENSIN II|Angiotensin II|Product containing angiotensin II (medicinal product)|Angiotensin II-containing product|Angiotensin II (substance)|5-L-isoleucineangiotensin II | angiotensin II |
C0022709 | A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) | Carboxycathepsin|Kininase II|Peptidyl Dipeptidase A|Kininase A|Dipeptidyl Peptidase A|angiotensin converting enzyme|CD143 Antigens|Peptidyl-Dipeptidase A|Antigens, CD143|Peptidyl-dipeptidase A|dipeptidyl peptidase|Angiotensin converting enzyme|Dipeptidyl carboxypeptidase I|angiotensin-converting enzyme|angiotensin converting enzymes|angiotensin i converting enzyme|Dipeptidyl carboxypeptidase I (substance)|Peptidase P|Angiotensin I Converting Enzyme|ACE - Angiotensin-converting enzyme|kininase|peptidyl dipeptidase A|angiotensin converting enzyme i|Angiotensin I-Converting Enzyme|Angiotensin Converting Enzyme | Peptidyl-Dipeptidase A |
C0055673 | A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation. | Chymase|Chymase 1|mast cell protease I|Chymotrypsin-Like Protease|Chymase (substance)|skeletal muscle protease|Chymotrypsin-Like Proteases|Chymases|Chymotrypsin Like Proteases|Skeletal muscle (SK) protease|chymase|Mast cell protease 1|Chymase-1|Chymotrypsin Like Protease | Chymase |
C0055673 | A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation. | Chymase|Chymase 1|mast cell protease I|Chymotrypsin-Like Protease|Chymase (substance)|skeletal muscle protease|Chymotrypsin-Like Proteases|Chymases|Chymotrypsin Like Proteases|Skeletal muscle (SK) protease|chymase|Mast cell protease 1|Chymase-1|Chymotrypsin Like Protease | Chymase |
C0600520 | null | Ventricle Remodeling, Left|Left Ventricular Remodelings|Remodeling, Left Ventricular|Left Ventricle Remodeling|Ventricular Remodelings, Left|Ventricle Remodelings, Left|left ventricular remodeling|Ventricular Remodeling, Left|Left Ventricle Remodelings|Remodelings, Left Ventricle|Remodeling, Left Ventricle|Left Ventricular Remodeling|Remodelings, Left Ventricular | Left Ventricle Remodeling |
C0919472 | Variants of proto-oncogenes that are members of the MYC family of early response genes, which encode regulatory proteins that act as homo- or hetero-dimers. These aberrant genes are activated by mutations or amplification, resulting in overexpression of the protein products. This can cause uncontrolled cell proliferation. | null | MYC-Family Oncogene |
C0919472 | Variants of proto-oncogenes that are members of the MYC family of early response genes, which encode regulatory proteins that act as homo- or hetero-dimers. These aberrant genes are activated by mutations or amplification, resulting in overexpression of the protein products. This can cause uncontrolled cell proliferation. | null | MYC-Family Oncogene |
C0003009 | An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. | Angiotensin-(1-8) Octapeptide|angiotensin ii|ANG-(1-8)Octapeptide|Angiotensin 2|2 angiotensin|angiotensin 2|angiotensin II|isoleucine5-angiotensin II|Angiotonin|ANGIOTENSIN II|Angiotensin II|Product containing angiotensin II (medicinal product)|Angiotensin II-containing product|Angiotensin II (substance)|5-L-isoleucineangiotensin II | angiotensin II |
C1514758 | Any intercellular signaling process in which a transmembrane or intracellular receptor in the responding cell binds to a cognate ligand and initiates an intracellular response. Receptor activation is involved in numerous processes, including metabolism, immune response, sexual development, nervous system function, and regulation of circadian rhythms, mood and behavior. | Receptor Activation|receptor activation | Receptor Activation Process |
C0225828 | Striated muscle cells found in the heart. They are derived from cardiac myoblasts (MYOBLASTS, CARDIAC). | Cardiocyte|Cardiac muscle fiber|Muscle Cells, Cardiac|myocardial cell|cardiomyocytes|Cell, Cardiac Muscle|Heart Muscle Cells|Cardiac myocyte, NOS|Muscle Cells, Heart|Myocytes, Cardiac|Cardiac Myocytes|Cells, Heart Muscle|Muscle Cell, Cardiac|Cells, Cardiac Muscle|Cardiac Muscle Cells|cardiac muscle cell|Cardiac myofiber|cardiac myocytes|Cell, Heart Muscle|Cardiac myocyte (cell)|Muscle Cell, Heart|cardiomyocyte|Myocyte, Cardiac|Myocytus cardiacus|Set of cardiac muscle cells|Contractile myocyte|Cardiac Muscle Cell|cells myocardial|cardiac myocyte|Cardiac Myocyte|Cardiomyocytes|Cardiac muscle cell|cardiac muscle cells|cardiac fibers muscle|Cardiac myocyte|Myocardial cell|Heart Muscle Cell|Cardiomyocyte|Set of cardiac myocytes | Myocytes, Cardiac |
C0376541 | A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo). Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04) | Erythropoiesis stimulating factor|Erythropoietin|ERYTHROPOIETIN|erythropoietin recombinant|SH-polypeptide-72|Hematopoietin|recombinant erythropoietin|Erythrocyte Colony Stimulating Factor|Recombinant EPO|Erythropoietin (recombinant human)|ESF|r-HuEPO|Erythropoietin (human, recombinant)|Recombinant Erythropoietin | Recombinant Erythropoietin |
C0014822 | Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation. | epos|EPO - Erythropoietin|hematopoietin|Erythropoietin|Erythropoietin preparation|erythropoietin|Epo|Product containing erythropoietin (medicinal product)|erythropoietins|Erythropoietin (substance)|E.P.O.|ECSF|Erythropoietin-containing product|erythrocyte colony stimulating factor|ECSF (erythrocyte colony stimulating factor)|Erythropoetin|epo | Erythropoietin |
C0014822 | Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation. | epos|EPO - Erythropoietin|hematopoietin|Erythropoietin|Erythropoietin preparation|erythropoietin|Epo|Product containing erythropoietin (medicinal product)|erythropoietins|Erythropoietin (substance)|E.P.O.|ECSF|Erythropoietin-containing product|erythrocyte colony stimulating factor|ECSF (erythrocyte colony stimulating factor)|Erythropoetin|epo | Erythropoietin |
C0016976 | A storage reservoir for BILE secretion. Gallbladder allows the delivery of bile acids at a high concentration and in a controlled manner, via the CYSTIC DUCT to the DUODENUM, for degradation of dietary lipid. | gallbladder|GALLBLADDER|Gallbladder|gall bladder|Vesica biliaris (Fellea)|Gall Bladder|Vesica biliaris|Gallbladder, NOS|Gallbladder structure|gallbladder structure|Gastrointestinal Tract, Gall Bladder|Gall bladder|Gallbladder / Biliar|Gallbladder structure (body structure)|Gallenblase|Gallbladders|Vesica fellea | Gallbladder |
C0387349 | null | null | cacospongionolide B |
C0387349 | null | null | cacospongionolide B |
C0010132 | A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. | Corticotropin releasing hormone|corticoliberin|Corticotropin-releasing factor|ACTH Releasing Factor|Corticotropin releasing factor (substance)|ACTH releasing factor|CRH - Corticotrophin releasing hormone|corticorelin|Corticotropin Releasing Factor|crh|Corticotropin Releasing Hormone|CRF-41|Corticotrophin releasing hormone|CRF (ACTH)|Corticotropin-Releasing Hormone|CRH (corticotropin releasing hormone)|CRF preparation|Corticotropin-Releasing Factor-41|ACTH-Releasing Factor|corticotropin releasing hormone|corticotropin releasing factor|Corticotropin releasing factor|Corticotropin-Releasing Factor|Corticotropin Releasing Hormone 41|CRF - Corticotrophin releasing factor|Corticotropin releasing factor-containing factor|ACTH-Releasing Hormone|CORTICORELIN|Product containing corticotropin releasing factor (product)|Corticotropin Releasing Factor 41|crf|Corticotrophin releasing factor|Corticotropin-Releasing Hormone-41|ACTH Releasing Hormone|Corticotropin releasing factor preparation|corticotropin-releasing factor|Corticotropin releasing factor (CRF)|corticotropin-releasing hormone|corticotropin RH|CRH|Corticoliberin|CRF | corticotropin-releasing hormone |
C0010132 | A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. | Corticotropin releasing hormone|corticoliberin|Corticotropin-releasing factor|ACTH Releasing Factor|Corticotropin releasing factor (substance)|ACTH releasing factor|CRH - Corticotrophin releasing hormone|corticorelin|Corticotropin Releasing Factor|crh|Corticotropin Releasing Hormone|CRF-41|Corticotrophin releasing hormone|CRF (ACTH)|Corticotropin-Releasing Hormone|CRH (corticotropin releasing hormone)|CRF preparation|Corticotropin-Releasing Factor-41|ACTH-Releasing Factor|corticotropin releasing hormone|corticotropin releasing factor|Corticotropin releasing factor|Corticotropin-Releasing Factor|Corticotropin Releasing Hormone 41|CRF - Corticotrophin releasing factor|Corticotropin releasing factor-containing factor|ACTH-Releasing Hormone|CORTICORELIN|Product containing corticotropin releasing factor (product)|Corticotropin Releasing Factor 41|crf|Corticotrophin releasing factor|Corticotropin-Releasing Hormone-41|ACTH Releasing Hormone|Corticotropin releasing factor preparation|corticotropin-releasing factor|Corticotropin releasing factor (CRF)|corticotropin-releasing hormone|corticotropin RH|CRH|Corticoliberin|CRF | corticotropin-releasing hormone |
C0162703 | Amount of stimulation required before the sensation of pain is experienced. | Quality of pain sense|Pain tolerance level|sensitivity pain|Threshold, Pain|Pain Tolerance Level|Pain threshold (observable entity)|Pain tolerance level (observable entity)|Pain Thresholds|PAIN SENSITIVITY|Pain tolerance (observable entity)|pain tolerances|pain threshold|pain tolerance|Pain Threshold|Sensitivity to pain|Pain threshold|Thresholds, Pain|Pain Tolerance|pain sensitivity|Pain tolerance | Pain Threshold |
C0005210 | A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN. | beta-endorphin|Beta endorphin (substance)|beta Endorphin|beta endorphins|Beta Endorphin|Endorphin, beta|beta-Endorphin (1-31)|Beta endorphin|beta-Endorphin|beta endorphin|B endorphin | beta-Endorphin |
C0001655 | An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). | Adrenocorticotropic hormone (substance)|CCTROP|adrenotrophin|Corticotrophin|adrenocorticotropic hormone|1-39 ACTH|Adrenocorticotropic hormone|acth hormone|Adrenocorticotropic Hormone|adrenotropin|adrenotropic hormone|Hormone, Adrenocorticotrophic|Corticotropin preparation|Adrenocorticotropin|Corticotropin|ACTH preparation|Adrenocorticotropic hormone (ACTH)|corticotropins|ACTH (1-39)|adrenocorticotropin|Adrenocorticotrophic hormone|Corticotropin (1-39)|corticotrophins|Hormone, Adrenocorticotropic|adrenocorticotrophic hormone|ACTH - Adrenocorticotrophic hormone|CORTICOTROPIN|Corticotrophin (1-39)|ACTH|Adrenocorticotrophic Hormone|Adrenocorticotropic hormone preparation|adrenocorticotropic hormone (ACTH)|adrenocorticotropic peptide|corticotropin|Adrenocorticotrophin|corticotrophin | corticotropin |
C0010366 | The reciprocal exchange of segments at corresponding positions along pairs of homologous CHROMOSOMES by symmetrical breakage and crosswise rejoining forming cross-over sites (HOLLIDAY JUNCTIONS) that are resolved during CHROMOSOME SEGREGATION. Crossing-over typically occurs during MEIOSIS but it may also occur in the absence of meiosis, for example, with bacterial chromosomes, organelle chromosomes, or somatic cell nuclear chromosomes. | Crossing-Over, Genetic|Crossing over (Genetics)|crossing over|cross over|genetic crossing over|Crossing Overs|Genetic crossing over (finding)|nonsister chromatid exchange|Genetic Crossing-Over|Crossing Over|Genetic crossing over|Genetic Crossing Over | Crossing Over, Genetic |
C0302559 | Surgical insertion of an electronic hearing device (COCHLEAR IMPLANTS) with electrodes to the COCHLEAR NERVE in the inner ear to create sound sensation in patients with residual nerve fibers. | cochlea implants|Insertion of cochlear implant|cochlear implant procedure|Prosthesis Implantation, Cochlear|cochlear implantation|Implantation of cochlear prosthetic device, NOS|Cochlear Implantations|Implantation of cochlear prosthetic device (procedure)|Implantation, Cochlear|Implantation of cochlear prosthetic device|Implantation, Cochlear Prosthesis|Cochlear Prosthesis Implantation|cochlear implant|Implantations, Cochlear|cochlea implant|cochlear implant procedures|Cochlear Prosthesis Implantations|Cochlear Implantation|Cochlear Implants|Prosthesis Implantations, Cochlear|Implantations, Cochlear Prosthesis | Cochlear implant procedure |
C0281825 | null | disorders equilibrium|DYSEQUILIBRIUM|DYSEQUILIBRIA|Disequilibrium|disequilibrium|dysequilibrium | Dysequilibrium |
C0078257 | A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. | Vinorelbine (substance)|Vinorelbine|C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-|nor-5'-Anhydrovinblastine|5'-Nor-Anhydrovinblastine|3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine|Vinorelbina|Vinorelbinum|Product containing vinorelbine (medicinal product)|Dihydroxydeoxynorvinkaleukoblastine|VINORELBINE|5'-Nor-anhydrovinblastine|Vinorelbin|5' Nor anhydrovinblastine|Vinorelbine-containing product|5'-Noranhydrovinblastine|vinorelbine|NVB | vinorelbine |
C0078257 | A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. | Vinorelbine (substance)|Vinorelbine|C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-|nor-5'-Anhydrovinblastine|5'-Nor-Anhydrovinblastine|3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine|Vinorelbina|Vinorelbinum|Product containing vinorelbine (medicinal product)|Dihydroxydeoxynorvinkaleukoblastine|VINORELBINE|5'-Nor-anhydrovinblastine|Vinorelbin|5' Nor anhydrovinblastine|Vinorelbine-containing product|5'-Noranhydrovinblastine|vinorelbine|NVB | vinorelbine |
C0008838 | An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. | CISPLATIN|cis-platinous diamine dichloride|Peyrone's Salt|Cis-diamminedichloro Platinum (II)|cis-platinum|CACP|CPDD|cis-diamminedichloridoplatinum|platinum diamminodichloride|cis-Platinum II|cis-platinum II|Cis-platinum II|C.I. 77795|Cis-platinum II Diamine Dichloride|cis-DDP|Cisplatin (substance)|cis-Diamminedichloroplatinum|CDDP|(SP-4-2)-diamminedichloroplatinum|cis diamminedichloroplatinum|Diamminodichloride, Platinum|Cismaplat|Cisplatinum|cis Diamminedichloroplatinum|cis-Platinum|cis Platinum|cis-diammine-dichloroplatinum|Platinum, Diaminedichloro-, cis- (8CI)|Peyrone's Chloride|cisplatinum|Platinum, diamminedichloro-, (SP-4-2)-|cis-diamminedichloroplatinum|PDD|Cisplatina|cis-Platinum compound, NOS|DDP|Cis-platinous Diamine Dichloride|platinum, diaminedichloro-, cis- (8CI)|cis platinum compound|Diaminedichloroplatinum|cisplatino|cis-Platinum compound|Cis-dichloroammine Platinum (II)|cis dichlorodiammineplatinum|cis-diamminedichloro platinum (II)|cis-platinum II diamine dichloride|CISplatin|cis platinum|Cisplatin-containing product|Dichlorodiammineplatinum|Cis-platinum|cis-diamminedichloroplatinum(II)|Cysplatyna|Platinoxan|cis-Diamminedichloroplatinum(II)|cis-Diaminedichloroplatinum|Platinum Metallicum|cisplatin|Cis-diamminedichloridoplatinum|(SP-4-2)-Diamminedichloroplatinum|Cis-DDP|Platinum Diamminodichloride|Cisplatin|Cis-diammine-dichloroplatinum|Product containing cisplatin (medicinal product)|cis-Dichlorodiammineplatinum(II)|Cis-diamminedichloroplatinum | cisplatin |
C0079083 | An organoplatinum compound that possesses antineoplastic activity. | carboplatin|Carboplatin (substance)|Product containing carboplatin (medicinal product)|Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-|cis-diammine(1,1-cyclobutanedicarboxylato)platinum|cbdca|CBDCA|cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)|Carboplatine|Carboplatin|cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)|Carboplatin-containing product|cis-diammine(cyclobutane-1,1-dicarboxylato)platinum|1,1-cyclobutanedicarboxylic acid platinum complex|(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum|cis-diammine(cyclobutanedicarboxylato)platinum II|Carboplatino|Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum|cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)|Carboplatinum|CARBOplatin|CARBOPLATIN|platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)|cis-Diammine(cyclobutanedicarboxylato)platinum II | carboplatin |
C0014582 | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Pidorubicine|Epirubicinum|Epirubicin-containing product|4'-Epidoxorubicin|4'-Epiadriamycin|Epiadriamycin|4' Epi Adriamycin|Pidorubicina|epirubicin|Epi DX|4'-Epi-DXR|EPIRUBICIN|4' Epi DXR|4'-Epi-Doxorubicin|(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione|4'-epi DX|Epirubicina|3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside|Product containing epirubicin (medicinal product)|4' Epi Doxorubicin|4' Epidoxorubicin|Epidoxorubicin|Epirubicin|Pidorubicinum|5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-|Epirubicin (substance)|4' Epiadriamycin|Pidorubicin|4'-Epi-Adriamycin|Epirubicine | epirubicin |
C0671970 | A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER. | Capécitabine|CAPE|N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine|Product containing capecitabine (medicinal product)|Capecitabine (substance)|5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine|Capecitabine-containing product|CAPECITABINE|Capecitabine|Capecitabina|Capecitabinum|pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate|capecitabine|Capecitabin|Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate|(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester | capecitabine |
C1559154 | null | Chemoradiation|Rash and Dermatitis Associated with Chemoradiation, CTCAE | Rash and Dermatitis Associated with Chemoradiation, CTCAE |
C1335729 | A neoplasm that does not respond to treatment. | Refractory Tumor | Refractory Neoplasm |
C0030200 | Persistent pain that is refractory to some or all forms of treatment. | intractable pain|Pains, Refractory|Intractable pain|Pains, Intractable|Intractable Pain|Pain, Refractory|Refractory Pains|Refractory Pain|Intractable Pains|refractory pain | Pain, Intractable |
C0596030 | Cells lining the saclike dilatations known as acini of various glands or the lungs. | Cells, Acinic|Acini Cell|Cell, Acinus|Acinus Cell|Cell, Acinar|acinar cell|acinar cells|Cells, Acinous|Cells, Acinar|Cell, Acini|Acinic Cell|Acinar cell|Acinar Cells|Cells, Acini|Acinous Cells|Cell, Acinic|Acinous Cell|Cell, Acinous|Acinic Cells|Acinar Cell|Acinus Cells|Acini Cells|Cells, Acinus | Acinar Cell |
C0232786 | null | functioning pancreatic|PANCREATIC FUNCTIONS|function pancreatic|pancreatic function|Pancreatic function (observable entity) | Pancreatic function |
C1268567 | Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation. | Protein Tyrosine Kinase Inhibitors|Product containing protein-tyrosine kinase inhibitor (product)|PTK Inhibitors|Protein-tyrosine kinase inhibitor-containing product|Protein-tyrosine kinase inhibitor|Tyrosine Kinase Inhibitor|Substance with protein-tyrosine kinase inhibitor mechanism of action (substance)|tyrosine kinase inhibitor|Substance with protein-tyrosine kinase inhibitor mechanism of action|TK Inhibitors | Protein-tyrosine kinase inhibitor |
C1567379 | null | AMN107|AMN 107 | AMN107 |
C0026207 | Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. | Miotic, NOS|miotics|pupillary constrictor|Miotic agent|MIOTICS|Miotic|miotic|Miotics|Miotic (substance)|Medicinal product acting as miotic (product) | Miotics |
C0038738 | Chemical agents that react with SH groups. This is a chemically diverse group that is used for a variety of purposes. Among these are enzyme inhibition, enzyme reactivation or protection, and labelling. | Reagents, Thiol|Reagents, Sulfhydryl|SH-Reagents|SH Reagents|Thiol Reagents|sulfhydryl reagent | Sulfhydryl Reagents |
C0083536 | A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension. | Ng-nitro-L-arginine methyl ester|N(omega)-Nitro-L-arginine Methyl Ester|NG Nitro L Arginine Methyl Ester|N-nitro-arginine methyl ester|N-omega-nitro-L-arginine methyl ester|L-NAME|N omega-Nitro-L-arginine Methyl Ester|N(G)-Nitro-L-arginine Methyl Ester|NG-Nitro-L-Arginine Methyl Ester|Methyl Ester, NG-Nitroarginine|NG Nitroarginine Methyl Ester|N omega Nitro L arginine Methyl Ester|N(G)-Nitroarginine Methyl Ester|Methyl Ester, NG-Nitro-L-Arginine | NG-Nitroarginine Methyl Ester |
C0178959 | null | adapters|adapter|ADAPTER | ADAPTER |
C0183115 | null | scanners|scanner|Scanner (physical object)|Scanner | Scanning Systems |
C0234378 | A type of tremors that is triggered by holding a limb in a fixed position. [HPO:probinson] | Tremor, Static|Tremor, postural|static tremor|Static Tremors|static tremors|Tremors, Static|postural tremor|Static tremor (finding)|Tremor, static|Static tremor|Postural tremor|postural tremors | Static Tremor |
C0949655 | DNA locations with the consensus sequence CANNTG. ENHANCER ELEMENTS may contain multiple copies of this element. E-boxes play a regulatory role in the control of transcription. They bind with basic helix-loop-helix (bHLH) type TRANSCRIPTION FACTORS. Binding specificity is determined by the specific bHLH heterodimer or homodimer combination and by the specific nucleotides at the 3rd and 4th position of the E-box sequence. | E Box Sequences|Elements, E-Box|E-Box Sequence|E-Box Sites|Sequence, E-Box|E Box Elements|E-Box Motifs|E Box Sites|Sites, E-Box|Site, E-Box|E-Box Element|Element, E-Box|E Box Motifs|E-Box Sequences|Motifs, E-Box|E-Box Motif|Motif, E-Box|Sequences, E-Box|E-Box Site | E-Box Elements |
C0876926 | A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain. | traumatic brain injury|brain injury traumatic|TBIs (Traumatic Brain Injuries)|Traumatic Encephalopathies|Trauma, Brain|Encephalopathy, Traumatic|brain trauma|Brain Traumas|TBI (Traumatic Brain Injuries)|traumatic brain damage|Brain Injuries, Traumatic|Traumatic encephalopathy|Traumatic Brain Injury|Brain Trauma|Traumatic brain injury (disorder)|TBI (Traumatic Brain Injury)|traumatic encephalopathy|brain traumas|Encephalopathies, Traumatic|TBI (traumatic brain injury)|TBI|Traumatic brain injury|Traumas, Brain|Injury, Brain, Traumatic|Traumatic Brain Injuries|Traumatic Encephalopathy|traumatic brain injuries|brain injuries traumatic|Brain Injury, Traumatic | Traumatic Brain Injury |
C1552160 | <p>Supernumerary mandibular right primary canine</p> | Rs | Supernumerary mandibular right primary canine |
C0021704 | The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions. | Intelligence, function (observable entity)|Intelligence, NOS|Intelligence, function|intelligence|Intelligence | Intelligence |
C0050941 | null | AG-1812 | AG 1812 |
C0235198 | Deterioration in the ability to concentrate. | unable to concentrate|lack of concentration|inability to concentrate|inability to maintain attention|concentrate inability|MENTAL CONCENTRATION DIFFICULTY|Impaired concentration|Lack of concentration|Unable to concentrate|concentration difficulties|concentration difficulty|difficulty concentration|CONCENTRATION IMPAIRMENT|Unable to concentrate (finding)|Poor concentration|impaired concentration|Concentration difficulties|CONCENTRATION IMPAIRED|Diminished ability to concentrate|concentration lack|Concentration impairment|concentration loss|Concentration Difficulty|CONCENTRATION (MENTAL) ABNORMAL|lack concentration|disturbed mental concentration|Concentration Impairment | Unable to concentrate |
C0917801 | Difficulty in going to sleep or getting enough sleep. | Insomnia, NOS|INSOMNIA|Insomnias|SLEEPLESSNESS|Insomnia, unspecified|insomnia|Insomnia (disorder)|Sleeplessness|Insomnia Disorder|Insomnia Disorders|Difficulty staying or falling asleep|sleeplessness|Insomnia | Sleeplessness |
C0237123 | Consumption of medicines, recreational drugs, or other materials likely to cause mood changes and/or psychological/physical dependence, illness, and disease. | alcohol drug use|Substance use|drug alcohol use|use (alcohol, drug)|substances use|AOD use|alcohol and other drug use|substance use|Alcohol or Other Drugs use|alcohol drugs use | Alcohol or Other Drugs use |
C0700132 | Level of engagement in educationally purposeful activities, satisfaction, acquisition of desired knowledge, skills, and competencies, persistence and attainment of educational outcomes. | Achievement, Academic|educational achievement|Success, Academic|academic achievement|Achievements, Academic|Academic achievement|educational attainment|Academic Achievement|Academic Successes|attainment educational|student achievement|scholastic achievement|Academic Achievements|achievement students|Academic Success|academic standing|achievement school|academic success|school achievement|Successes, Academic | Academic achievement |
C0038586 | null | AODD|Disorder, Substance Use|AOD use disorders|substance use disorders|Substance Use Disorder|alcohol or other drug use disorders|Alcohol or Other Drugs use disorders|substance use disorder|alcohol and other drug use pathology|chemical use disorders|disorder substance use|SUBSTANCE USE DISORDER|Alcohol or Other Drug Disorder | Substance Use Disorders |
C0005586 | A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. | Manic-Depressive Psychosis|Bipolar affective disorder|bipolar disorders|Manic-depressive syndrome NOS|Bipolar disorder, NOS|Psychosis, Manic-Depressive|manic depressive disorder|Psychoses, Manic-Depressive|Bipolar disorder NOS|Manic-Depressive Illness|BIPOLAR DISORDERS|Psychoses, Manic Depressive|Manic-depressive reaction NOS|Disorder, Bipolar|Psychosis, Bipolar Affective|bipolar affective psychosis|Manic Depressive Psychosis|affective bipolar disorders|BPAD|bipolar affective disorder|REACTION MANIC-DEPRESSIVE|Bipolar Affective Psychosis|Manic-depressive illness|Affective Psychosis, Bipolar|Bipolar Disorders|manic depression|Manic-Depression|Psychosis, Manic Depressive|PSYCHOSIS MANIC-DEPRESSIVE|Manic-depressive psychosis|bipolar mood disorder|affective bipolar disorder|bipolar disorder|bipolar disorder nos|Psychoses, Bipolar Affective|manic-depressive disorders|manic depressive|MDI - Manic-depressive illness|manic depressive psychosis|Manic Depressive Disorder|manic depressive illness|Bi-polar Disorder|Manic-Depressive Psychoses|manic-depressive illness|manic depressions|Bipolar Disorder|Bipolar disorder|BIPOLAR AFFECTIVE DISORDER|bipolar illness|Bipolar disorder (disorder)|Bipolar disorder, unspecified|MANIC DEPRESSIVE REACTION|MANIC DEPRESSIVE ILLNESS|manic-depressive psychosis | Bipolar Disorder |
C0036337 | A disorder in which the individual suffers from both symptoms that qualify as schizophrenia and symptoms that qualify as a mood disorder (e.g., depression or bipolar disorder) for a substantial portion (but not all) of the active period of the illness; for the remainder of the active period of the illness, the individual suffers from delusions or hallucinations in the absence of prominent mood symptoms. | Schizoaffective schizophrenia|Schizophreniform psychosis, affective type|Schizophrenia, schizo-affective type|Disorders, Schizoaffective|Schizoaffective disorder|Schizo-affective type|Disorder, Schizoaffective|SCHIZOAFFECTIVE DISORDER|Schizoaffective disorder (disorder)|schizoaffective-type schizophrenia|Schizoaffective disorder, NOS|schizoaffective disorders|schizoaffective psychosis|Schizoaffective Disorder|Schizoaffective schizophrenia (disorder)|affective disorder schizo|schizo affective disorder|schizoaffective disorder|disorder schizoaffective|SCHIZO AFFECTIVE SCHIZOPHRENIA|schizoaffective schizophrenia|Schizoaffective Disorders|Schizo-affective psychosis | Schizoaffective Disorder |
C0282541 | A late-appearing component of the event-related potential. P300 stands for a positive deflection in the event-related voltage potential at 300 millisecond poststimulus. Its amplitude increases with unpredictable, unlikely, or highly significant stimuli and thereby constitutes an index of mental activity. (From Campbell, Psychiatric Dictionary, 6th ed) | P3 Event Related Potentials|P300 Component|P300 Event Related Potentials|Event-Related Potential, P3|P300 Event-Related Potentials|Event Related Potentials, P300|P300 Event-Related Potential|Evoked Potentials, P300 Component|Event-Related Potentials, P3|P300 Components|P3 Event-Related Potentials|P3 Event-Related Potential|Event-Related Potential, P300|Event Related Potentials, P3 | Event-Related Potentials, P300 |
C0282171 | null | Event-related potentials, function|event related potential|Event-Related Potentials|Potentials, Event Related|Event Related Potentials|Potential, Event-Related|Event-Related Potential|Event-related potentials, function (observable entity)|event-related potential|ERP (event related potential)|event-related potentials|Event-related potentials|ERP - Event-related potentials|event related potentials | Potentials, Event-Related |
C0424318 | Aggressive behavior by a more powerful party that results in physical harm to or emotional distress of the victim. | bullis|bullied|Bullying|bullies|Bullying (finding)|bullying|bully | Bullying |
C0474404 | null | victimization|victimisation | Victimizing others |
C0683321 | A response indicating that an individual was in poor health. | health poor|poor health|Poor Health | Poor Health |
C0683323 | null | disorders physical|physical disorders|illness physical|physical disorder|Physical Illness|disorder physical | physical illness |
C0022107 | Abnormal or excessive excitability with easily triggered anger, annoyance, or impatience. | irritability|Mood, Irritable|Irritable Mood|Fussiness|Irritibility|Irritable Moods|Moods, Irritable|Irritability|irritable|fussiness|IRRITABILITY|irritable mood|Feeling irritable|Irritable mood|Irritable|Feeling irritable (finding) | Irritable Mood |
C1523298 | A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. [GOC:dph, PMID:14701881] | Transition, Epithelial-Mesenchymal|Epithelial Mesenchymal Transformation|epithelial to mesenchymal transition|Epithelial Mesenchymal Transition|epithelial-mesenchymal transition|EMT|Transformations, Epithelial-Mesenchymal|Transformation, Epithelial-Mesenchymal|Epithelial-Mesenchymal Transition|Epithelial-to-Mesenchymal Transition|Epithelial-to-mesenchymal transformation|Epithelial-Mesenchymal Transformations|Epithelial to Mesenchymal Transition|Epithelial-Mesenchymal Transformation|Epithelial-Mesenchymal Transitions|mesenchymal cell differentiation from epithelial cell|Transitions, Epithelial-Mesenchymal | epithelial to mesenchymal transition |
C0877453 | null | null | acute cellular rejection |
C1180121 | null | tributaries|tributary | Tributary |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.